Eli Lilly and Company (LLY) Aandelenanalyse

Bedrijfsoverzicht

Eli Lilly and Company function as a comprehensive pharmaceutical entity dedicated to the discovery, development, manufacturing, and marketing of human pharmaceutical products across the United States, Europe, China, Japan, and international markets. The firm operates within the Healthcare sector and specifically targets the Drug Manufacturers - General industry, positioning itself as a critical provider of therapeutic solutions for cardiometabolic health and other medical needs. This massive enterprise commands a substantial market capitalization of $840.84B, supported by an annual revenue stream of $65.18B and a workforce comprising 50,000 employees. These valuation and revenue figures collectively indicate that the company holds a dominant position in the global pharmaceutical landscape, reflecting the immense scale of its operations and its significant influence within the healthcare ecosystem.

Financiële gezondheid

The company generated $65.18B in revenue during the trailing twelve months, resulting in a net income of $20.64B and an EBITDA of $31.69B, highlighting a robust ability to convert sales into profit before interest and taxes. The substantial gap between the $65.18B revenue and the $20.64B net income reveals a significant cost structure that includes substantial expenses related to research, development, manufacturing, and general administration, yet still allows for a highly profitable bottom line. Free cash flow stands at $1.95B, which indicates the cash remaining after capital expenditures and operating costs, providing the company with financial flexibility to fund future innovation, repay debt, or return capital to stakeholders. Profitability is further evidenced by three key margins: a gross margin of 83.0%, an operating margin of 44.9%, and a profit margin of 31.7%, where the high gross margin suggests strong pricing power and cost efficiency in production, while the operating and profit margins reflect effective control over operational expenses and overall profitability. The balance sheet shows $7.27B in cash against $43.87B in total debt, resulting in a debt-to-equity ratio of 165.31, which characterizes the capital structure as leveraged given the significant debt relative to equity, though the high cash position helps mitigate immediate liquidity pressures. Short-term liquidity is supported by a current ratio of 1.58, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. Management effectiveness is underscored by a return on equity of 101.2% and a return on assets of 19.4%, metrics that demonstrate highly efficient utilization of shareholder capital and assets to generate returns well above industry averages.

Waarderingsbeoordeling

Valuation metrics present a mixed picture with a trailing P/E ratio of 40.99 compared to a forward P/E of 22.33, suggesting that the market currently prices in a significant expected increase in future earnings that is not yet reflected in trailing figures. The price-to-book ratio stands at 31.68, indicating a substantial market premium over the company's book value, which is typical for high-growth pharmaceutical firms with significant intangible assets like intellectual property. Alternative valuation measures include a price-to-sales ratio of 12.90 and an EV/EBITDA of 27.64, which suggest that the market is willing to pay a high multiple relative to both sales and earnings before interest, taxes, depreciation, and amortization. Price action over the last year ranges between a 52-week low of $623.78 and a 52-week high of $1133.95, though the specific current trading price is not provided in the available data to calculate the exact percentage deviation from these range limits. The stock exhibits a beta of 0.50, meaning its price volatility is significantly lower than the broader market, suggesting it may move less drastically in response to general market fluctuations compared to a benchmark index.

Growth & Income

Growth dynamics are characterized by a revenue growth rate of 42.6% year-over-year and an earnings growth rate of 51.4% year-over-year, indicating that earnings are expanding at a faster pace than revenue, which often implies improving operational leverage, favorable pricing actions, or efficiency gains in the cost structure. As a dividend payer, the company offers a dividend yield of 0.7% with a payout ratio of 26.1%, a low payout ratio that suggests the company retains the majority of its earnings for reinvestment while maintaining a sustainable and manageable dividend obligation relative to its profitability. Given the robust earnings growth and the low payout ratio, the company prioritizes reinvesting earnings into research, development, and business expansion rather than maximizing immediate dividend payouts. The overall profile combines high growth rates with a conservative dividend policy, reflecting a strategy focused on long-term value creation through organic growth and product pipeline expansion rather than immediate income distribution.